Risperdal Gets Approval For Adolescents; FDA Concerns Delay Zyprexa

Johnson & Johnson's Risperdal beat Lilly's Zyprexa as the first drug into the adolescent schizophrenia and bipolar I disorder market, with FDA approval for risperidone for the two indications Aug. 22

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet